November 10th, 2026Viridian's VRDN-008 sustains IgG suppression through 8 weeks in phase 1The half-life extended FcRn inhibitor showed a 74% peak reduction in IgG in healthy volunteers.Read more
November 5th, 2026Ophthalmic care uncommon after tamoxifen initiationFew people starting tamoxifen require an ophthalmic evaluation during the following year. Read more
October 31st, 2026Q&A: Phentolamine for presbyopia: a non-miotic route to near visionThe FDA approved the Supplemental New Drug Application for phentolamine 0.75% (Ryzumvi, Opus Genetics/Viatris) to treat presbyopia. Read more
November 16th, 2026Dazodalibep data put Sjögren screening in focus for ophthalmologistsA systemic Sjögren therapy would make earlier identification more actionable for ophthalmologists, Esen K. Akpek, MD, said.Read more
November 15th, 2026Q&A: What the FDA’s class-wide NAION warning on GLP-1s means for eye careVeeral S. Sheth, MD, MBA, FACS, FASRS, discusses the evidence behind the new labeling requirement and how it aligns with the AAO/NANOS consensus statement.Read more
November 14th, 2026How Lambert-Eaton myasthenic syndrome presents around the eyesAlfredo A. Sadun, MD, PhD, explains how LEMS mimics myasthenia gravis around the eyes and why its cancer link matters.Read more
November 13th, 2026The interplay between cardiac disease and the eyeJosef Huemer, MD, discusses retinal changes linked to atrial fibrillation and what they mean for eye care clinicians.Read more
November 13th, 2026OT Roundup: GLP-1 NAION warning, LEMS clues, Eyedaptic Eva, AFibThe FDA adds a NAION warning to GLP-1 drugs, plus LEMS clues, Eyedaptic's new Eva AI assistant and a retinal imaging link to AFib.Read more